Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


In Brief: Pillar Point Partners

This article was originally published in The Gray Sheet

Executive Summary

Pillar Point Partners: Files patent infringement suit Sept. 9 in the U.S. District Court for Arizona against Phoenix-based Barney Dulaney Eye Center. The suit charges Dulaney with "performing laser eye surgery without a license" from the Pillar Point partnership formed in 1992 to license Summit Technology's and Visx' excimer laser technology, according to a Sept. 10 Pillar Point press release. Pillar Point files a separate suit Sept. 9 in the U.S. District Court for the District of Columbia against Washington, D.C.-based consultant William Appler for allegedly "aiding and encouraging others, including eye clinics and medical personnel, to infringe the patented technology" of the partnership. Appler has represented ophthalmic surgeons that use custom-built and reimported excimer lasers for photorefractive keratectomy and laser in situ keratomileusis (LASIK), advising the physicians on FDA policy toward the unapproved lasers...

You may also be interested in...

Hikma Adds Sesen’s Vicineum To MENA Brands

Hikma and Sesen Bio have struck a deal that will see Hikma distribute the Vicineum brand in the MENA region.

Netherlands’ Norgine Sets Up OTC Business And Targets Acquisitions

By establishing a dedicated consumer healthcare subsidiary, Norgine is hoping it can grow its $200m-plus Movicol laxative brand and take advantage of M&A opportunities in the OTC market.

AAM Urges Supreme Court To Uphold Inter Partes Review

The AAM has insisted that the US Supreme Court should uphold the inter partes review framework, in an amicus brief filed as part of litigation that potentially threatens hundreds of IPR decisions.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts